COLL Collegium Pharmaceutical Inc.

Collegium to Host Conference Call to Discuss Third Quarter 2020 Financial Results and Provide Corporate Update

Collegium to Host Conference Call to Discuss Third Quarter 2020 Financial Results and Provide Corporate Update

STOUGHTON, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, November 5, 2020 at 4:30 p.m. Eastern Time. The Company will discuss its financial results and provide a corporate update.

Conference Call Information: 

To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Q3 Earnings Call.” An audio webcast will be accessible from the Investors section of the Company’s website: . The webcast will be available for replay on the Company’s website approximately two hours after the event.

About Collegium Pharmaceutical, Inc.

Collegium is a specialty pharmaceutical company committed to being the leader in responsible pain management. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the company’s website at .

Contact:

Alex Dasalla

EN
22/10/2020

Underlying

COLLCollegium Pharmaceutical Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Collegium Pharmaceutical Inc.

Free Trial
COLL Collegium Pharm...

Collegium Pharmaceutical Inc: 1 director

A director at Collegium Pharmaceutical Inc sold 30,000 shares at 40.525USD and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ...

COLL COLLEGIUM PHARMACEUTICAL INC.
11/07/25 November 7, 2025 1 EN
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 43.22
SGI SOMNIGROUP INTE...
ATNI ATN Internation... ... (+29)

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

SGI SOMNIGROUP INTERNATIONAL INC
ATNI ATN INTERNATIONAL INC.
PAHC PHIBRO ANIMAL HEALTH CORPORATION CLASS A
LGND LIGAND PHARMACEUTICALS INCORPORATED
PLNT PLANET FITNESS INC. CLASS A
HOO HERBALIFE NUTRITION LTD.
COLL COLLEGIUM PHARMACEUTICAL INC.
AMBA AMBARELLA INC.
SKY SKYLINE CHAMPION CORPORATION
NYT NEW YORK TIMES COMPANY CLASS A
DLX DELIGNIT AG
MTSI MACOM TECHNOLOGY SOLUTIONS HOLDINGS INC.
NOMDN NOMAD FOODS LTD.
LILA LIBERTY LATIN AMERICA A
DUBA DRDGOLD LTD. ADS
BW BABCOCK & WILCOX ENTERPRISES
SITM SITIME
LZ LEGALZOOM.COM INC
DERM JOURNEY MEDICAL CORP
COHR COHERENT CORP
GPCR STRUCTURE THERAPEUTICS
SBGI SINCLAIR INC
FBYD FALCONS BEYOND GLOBAL INC
MRX MAREX GROUP PLC
LB LANDBRIDGE COMPANY LLC
ORKA ORUKA THERAPEUTICS INC
ECG_w EVERUS CONSTRUCTION GROUP INC.
BKTI BK TECHNOLOGIES CORP
RAL RALLIANT CORP
11/07/25 November 7, 2025 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium Reports Third Quarter 2025 Financial Results; Raises 2025 Gu...

Collegium Reports Third Quarter 2025 Financial Results; Raises 2025 Guidance – Generated Record Quarterly Net Revenue of $209.4 Million, Up 31% Year-over-Year – – Generated Record Quarterly Jornay PM® Net Revenue of $41.8 Million; Grew Prescriptions by 20% Year-over-Year – – Generated Record Quarterly Pain Portfolio Net Revenue of $167.6 Million, Up 11% Year-over-Year, with All Three Core Products Growing Year-over-Year – – Raised Full-Year 2025 Net Revenue Guidance to be in the Range of $775 to $785 Million and Adjusted EBITDA Guidance in the Range of $460 to $470 Million – – Ended Q3...

November 6, 2025 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Paris Hilton Collaborates with Collegium Pharmaceutical to Share Her P...

Paris Hilton Collaborates with Collegium Pharmaceutical to Share Her Personal ADHD Journey and Experience with Treatment ​​​– Long-time advocate, Paris Hilton, shares her personal ADHD journey from childhood to adulthood to encourage others to speak to their healthcare provider about appropriate treatment options – STOUGHTON, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified biopharmaceutical company, and Paris Hilton, entrepreneur, musician, ​author, and advocate, ​are collaborating ​​to share her personal experience living ...

October 29, 2025 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium to Report Third Quarter 2025 Financial Results on November 6...

Collegium to Report Third Quarter 2025 Financial Results on November 6, 2025 STOUGHTON, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: COLL) today announced that it will report third quarter 2025 financial results before the market opens on Thursday, November 6, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 8:00 a.m. ET. Conference Call Information To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Pharmaceutical Q3 2025 Earnings Call.” An audio we...

October 23, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch